CoronaryAtlas logo
CoronaryAtlas
isocitrate
Pathway / Off-pathway / systemic markers

isocitrate

metabolite

Isocitrate dysregulation reflects myocardial energetic exhaustion and predicts both AMI diagnosis and major adverse cardiac events.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleTCA cycle intermediate; diagnostic and prognostic for AMI and MACE; metabolic failure marker.
Also acts inMyocardial injury
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
43
C — non-Type-I
77
A — assay feasibility
42
E — evidence strength
32
T1DI (composite)
4
Specificity differential (R−C)-34.3
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(3)